Combining Beta-Blockers with Other Agents for Palpitations

Primary Combination Strategy

The American Heart Association recommends combining beta-blockers with nondihydropyridine calcium channel blockers (diltiazem or verapamil) for palpitations inadequately controlled by beta-blockers alone, with cautious monitoring for bradycardia and hypotension 1, 2, 3
Beta-blocker plus diltiazem or verapamil is the evidence-based combination for persistent palpitations, particularly when single-agent therapy reduces heart rate to 110-120 beats/min but patients remain symptomatic with continued palpitations or discomfort 1, 2, 3
This combination is specifically indicated when patients still complain of palpitations despite beta-blocker monotherapy achieving partial rate control 2, 4
The combination may also serve as an alternative to avoid the toxic side effects of amiodarone 1, 3
Both agents work synergistically to slow heart rate, ideally targeting <100 beats/min (optimally <84 beats/min) to improve ventricular filling in diastole 1, 3

The NORDIL study demonstrated that beta-blocker plus diltiazem or verapamil combination is generally safe, with approximately 700 patients receiving this combination without reported syncope or need for pacemaker implantation 1, 2, 3
In clinical practice, severe bradycardia requiring pacemaker treatment was reported in only very few patients 1, 2
However, worsening heart failure can occur in selected patients due to excessive negative inotropic and chronotropic effects 1, 2

The American College of Cardiology recommends avoiding this combination in patients with decompensated heart failure with reduced ejection fraction (nondihydropyridine calcium channel blockers have pronounced negative inotropic effects) 1, 5

The American College of Cardiology suggests that a combination of digoxin with either a beta-blocker or nondihydropyridine calcium channel blocker is reasonable to control heart rate both at rest and during exercise in patients with palpitations 6, 7
This combination is particularly useful for patients with heart failure or left ventricular dysfunction 6, 7

If combination therapy with beta-blocker plus calcium channel blocker fails to control symptoms, amiodarone becomes the remaining treatment choice, usually combined with a beta-blocker 1, 2
Oral amiodarone may be considered when resting and exercise heart rate cannot be adequately controlled using other combinations 6, 5
AV node ablation with ventricular pacing may be considered when pharmacological therapy is insufficient or not tolerated 5

Diltiazem and verapamil inhibit P-glycoprotein and CYP450 3A4, affecting metabolism of multiple cardiovascular drugs, which may increase levels of direct oral anticoagulants, thereby increasing bleeding risk 1
The American Heart Association recommends avoiding using nondihydropyridine calcium channel blockers in decompensated heart failure, as they may exacerbate hemodynamic compromise 5, 7